Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma

Alexander M.M. Eggermont, Christian U. Blank, Mario Mandala, Georgina V. Long, Victoria G. Atkinson, Stéphane Dalle, Andrew Haydon, Mikhail Lichinitser, Adnan Khattak, Matteo S. Carlino, Shahneen Sandhu, James Larkin, Susana Puig, Paolo A. Ascierto, Piotr Rutkowski, Dirk Schadendorf, Rutger Koornstra, Leonel Hernandez-Aya, Anna Maria Di Giacomo, Alfonsus JM van den EertweghJean Jacques Grob, Ralf Gutzmer, Rahima Jamal, Paul C. Lorigan, Robert Lupinacci, Clemens Krepler, Nageatte Ibrahim, Michal Kicinski, Sandrine Marreaud, Alexander C. van Akkooi, Stefan Suciu, Caroline Robert

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma'. Together they form a unique fingerprint.

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science